Investigating combined treatment methodologies is crucial for addressing the complex nature of cancer. As an emerging strategy, nano-biotechnology encourages the design of unique nanocarriers possessing simultaneous therapeutic application properties. This study aims to explore the combined effects of photodynamic and anticancer treatments using a multifunctional nanocarrier system co-administering the photosensitizer IR780 and the anticancer agent curcumin (Cur) on lung cancer cells. Nanocarriers were prepared by encapsulation IR780 and Cur inside polyethylene glycol-capped mesoporous silica nanoparticles (Cur&IR780@MSN). Various concentrations of nanocarriers were evaluated on A549 cells following 5 min NIR laser light (continuous wave, 785 nm, 500 mW/cm²) irradiation. The internalization of nanocarriers was observed through the fluorescence of Cur. Changes in cell viability were determined using the MTT assay and AO/PI staining. A scratch assay analysis was also performed to examine the impact of combined treatments on cell migration. Characterization of the nanocarriers revealed adequate hydrophobic drug loading, temperature-inhibited feature, enhanced reactive oxygen species generation, a pH-dependent curcumin release profile, and high biocompatibility. Cur&IR780@MSN, which enabled the observation of synergistic treatment efficacy, successfully reduced cell viability by up to 78%. In contrast, monotherapies with curcumin-loaded nanocarriers (Cur@MSN) and IR780-loaded nanocarriers (IR780@MSN) resulted in a 38% and 56% decrease in cell viability, respectively. The constructed Cur&IR780@MSN nanocarrier has demonstrated remarkable performance in the application of combination therapies for lung cancer cells. These nanocarriers have the potential to inspire future studies in tumor treatment methods.

研究联合治疗方法对于解决癌症的复杂性至关重要。作为一种新兴策略，纳米生物技术鼓励设计具有同时治疗应用特性的独特纳米载体。本研究旨在探索使用多功能纳米载体系统共同施用光敏剂 IR780 和抗癌剂姜黄素 (Cur) 的光动力和抗癌治疗对肺癌细胞的综合作用。通过将 IR780 和 Cur 封装在聚乙二醇封端的介孔二氧化硅纳米颗粒 (Cur&IR780@MSN) 内制备纳米载体。在近红外激光（连续波，785 nm，500 mW/cm ²）照射5分钟后，在A549细胞上评估不同浓度的纳米载体。通过 Cur 的荧光观察纳米载体的内化。使用 MTT 测定和 AO/PI 染色测定细胞活力的变化。还进行了划痕分析，以检查联合处理对细胞迁移的影响。纳米载体的表征揭示了足够的疏水性载药量、温度抑制特性、增强的活性氧生成、pH依赖性姜黄素释放特性以及高生物相容性。 Cur&IR780@MSN 能够观察协同治疗效果，成功降低细胞活力高达 78%。相比之下，使用姜黄素负载纳米载体 (Cur@MSN) 和 IR780 负载纳米载体 (IR780@MSN) 的单一疗法分别导致细胞活力下降 38% 和 56%。构建的Cur&IR780@MSN纳米载体在肺癌细胞联合治疗应用中表现出了卓越的性能。这些纳米载体有可能激发肿瘤治疗方法的未来研究。